Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395153 | 0.84 | KMT2A (0.43) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL5542734 | 0.82 | ALOX15 (0.52) | ALOX15KMT2ASMN1; SMN2RECQLLMNA | |
| SCHEMBL270238 | 0.78 | NCEH1 (0.38) | ALOX15SMN1; SMN2LMNAL3MBTL1HPGD | |
| SCHEMBL3828975 | 0.76 | NCEH1 (0.37) | ALOX15SMN1; SMN2LMNAL3MBTL1HPGD | |
| SCHEMBL31621484 | 0.76 | ELANE (0.46) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL1343624 | 0.76 | ELANE (0.46) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL4795365 | 0.75 | ESR1 (0.42) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL23887393 | 0.75 | ABL1 (0.61) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL30307545 | 0.75 | ABL1 (0.61) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 | |
| SCHEMBL11583309 | 0.75 | ESR1 (0.51) | ALOX15KMT2AESR1HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016154313-A1 | HIGH DRUG LOADING LIQUID ORAL PHARMACEUTICAL COMPOSITIONS | ZYWIE, LLC (US) | 2016-09-29 | — | — | WO | claimed |
| US-20140249233-A1 | METHOD FOR ENHANCING FOLDING AND TRANSPORT OF MISFOLDED GLUCOCEREBROSIDASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-09-04 | — | — | US | claimed |
| US-20140235713-A1 | METHOD OF TREATING LYSOSOMAL STORAGE DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-08-21 | — | — | US | claimed |
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-11-02 | — | — | US | disclosed |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-08-06 | — | — | US | disclosed |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-05-19 | — | — | US | disclosed |
| US-20180296502-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-10-18 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-20160331701-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | MCMASTER UNIVERSITY (CA) | 2016-11-17 | — | — | US | disclosed |
| WO-2016160469-A1 | DUAL CHAMBER SYRINGE FOR MIXING AND DISPENSING ORAL LIQUID PHARMACEUTICAL DOSAGE FORMS DIRECTLY IN THE MOUTH OF A PATIENT | ZYWIE, LLC (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016154313-A1 | HIGH DRUG LOADING LIQUID ORAL PHARMACEUTICAL COMPOSITIONS | ZYWIE, LLC (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20130184352-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-07-18 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-8404668-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-03-26 | — | — | US | disclosed |
| EP-2200596-B1 | METHOD OF TREATING GAUCHER DISEASE | HOSPITAL FOR SICK CHILDREN (CA) | 2012-06-13 | — | — | EP | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| EP-2200596-A1 | METHOD OF TREATING GAUCHER DISEASE | The Hospital For Sick Children (CA) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009038695-A1 | METHOD OF TREATING GAUCHER DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235713-A1 | METHOD OF TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | ALOX15 1722/4885KMT2A 3767/4885ESR1 4882/4885 |
| US-20090075960-A1 | Method of treating gaucher disease | GBA1, GAA, GBA3 | ALOX15 1508/4885KMT2A 3922/4885ESR1 4877/4885 |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-20140249233-A1 | METHOD FOR ENHANCING FOLDING AND TRANSPORT OF MISFOLDED GLUCOCEREBROSIDASE | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | ALOX15 1508/4885KMT2A 3922/4885ESR1 4877/4885 |
| US-20180296502-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-20160331701-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | ALOX15 2595/4885KMT2A 4621/4885ESR1 4877/4885 |
| US-20130184352-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | ALOX15 1508/4885KMT2A 3922/4885ESR1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.